U

United Laboratories International Holdings Ltd
HKEX:3933

Watchlist Manager
United Laboratories International Holdings Ltd
HKEX:3933
Watchlist
Price: 12.3 HKD 4.77% Market Closed
Market Cap: 22.3B HKD
Have any thoughts about
United Laboratories International Holdings Ltd?
Write Note

Net Margin
United Laboratories International Holdings Ltd

20.8%
Current
15%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
20.8%
=
Net Income
2.9B
/
Revenue
14B

Net Margin Across Competitors

Country HK
Market Cap 22.3B HKD
Net Margin
21%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 755.8B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 2.7T DKK
Net Margin
35%
Country US
Market Cap 351.1B USD
Net Margin
17%
Country US
Market Cap 251.8B USD
Net Margin
19%
Country CH
Market Cap 200.1B CHF
Net Margin
20%
Country UK
Market Cap 161.8B GBP
Net Margin
13%
Country CH
Market Cap 171.5B CHF
Net Margin
35%
Country US
Market Cap 151.5B USD
Net Margin
7%
No Stocks Found

United Laboratories International Holdings Ltd
Glance View

Market Cap
22.3B HKD
Industry
Pharmaceuticals

United Laboratories International Holdings Ltd. has carved a significant niche in the global pharmaceutical industry, primarily through its prowess in producing antibiotic finished products and intermediates. Headquartered in Hong Kong, the company operates a diversified business model that spans manufacturing, marketing, and distribution of a wide range of pharmaceutical products. United Laboratories has established robust production facilities in China, positioning itself as one of the leading producers of antibiotics like amoxicillin and ampicillin. These products are vital to combating infections and are critical components in healthcare systems worldwide. The company's vertically integrated operations, coupled with its strategic focus on research and development, enable it to maintain cost efficiency while innovating continuously within its drug portfolio. The company's revenue mechanism is firmly rooted in its extensive distribution network and expansive market reach, which traverse not only the domestic markets but also international territories in North America, Europe, and Asia. United Laboratories leverages its strong brand presence and economies of scale to offer competitive pricing, enhancing its market penetration. Furthermore, it capitalizes on favorable regulatory frameworks in emerging markets, creating a tapestry of growth opportunities. The company's business strategy is also marked by its commitment to quality and adherence to stringent production standards, essential for maintaining trust and reliability among healthcare providers. Through these strategic channels, United Laboratories International Holdings Ltd. sustains its growth and profitability in the dynamic pharmaceutical landscape.

Intrinsic Value
21.1 HKD
Undervaluation 42%
Intrinsic Value
Price
U

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
20.8%
=
Net Income
2.9B
/
Revenue
14B
What is the Net Margin of United Laboratories International Holdings Ltd?

Based on United Laboratories International Holdings Ltd's most recent financial statements, the company has Net Margin of 20.8%.